HUE032919T2 - Azaindazol- vagy diazaindazol-típusú származékok fájdalom kezelésére - Google Patents

Azaindazol- vagy diazaindazol-típusú származékok fájdalom kezelésére

Info

Publication number
HUE032919T2
HUE032919T2 HUE13745813A HUE13745813A HUE032919T2 HU E032919 T2 HUE032919 T2 HU E032919T2 HU E13745813 A HUE13745813 A HU E13745813A HU E13745813 A HUE13745813 A HU E13745813A HU E032919 T2 HUE032919 T2 HU E032919T2
Authority
HU
Hungary
Prior art keywords
azaindazole
derivatives
treating pain
diazaindazole
type
Prior art date
Application number
HUE13745813A
Other languages
English (en)
Hungarian (hu)
Inventor
Pierre Sokoloff
Frederic Cachoux
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HUE032919T2 publication Critical patent/HUE032919T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE13745813A 2012-07-27 2013-07-29 Azaindazol- vagy diazaindazol-típusú származékok fájdalom kezelésére HUE032919T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain

Publications (1)

Publication Number Publication Date
HUE032919T2 true HUE032919T2 (hu) 2017-11-28

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13745813A HUE032919T2 (hu) 2012-07-27 2013-07-29 Azaindazol- vagy diazaindazol-típusú származékok fájdalom kezelésére

Country Status (28)

Country Link
US (1) US9381195B2 (show.php)
EP (2) EP2689778A1 (show.php)
JP (2) JP6456823B2 (show.php)
KR (1) KR102120505B1 (show.php)
CN (1) CN104684554B (show.php)
AU (1) AU2013294920B2 (show.php)
BR (1) BR112015001502B1 (show.php)
CA (1) CA2879595C (show.php)
CY (1) CY1118478T1 (show.php)
DK (1) DK2877177T3 (show.php)
ES (1) ES2612349T3 (show.php)
HR (1) HRP20170104T1 (show.php)
HU (1) HUE032919T2 (show.php)
IL (1) IL236917A (show.php)
LT (1) LT2877177T (show.php)
MA (1) MA37866B1 (show.php)
MX (1) MX363605B (show.php)
MY (1) MY183398A (show.php)
NZ (1) NZ705253A (show.php)
PL (1) PL2877177T3 (show.php)
PT (1) PT2877177T (show.php)
RS (1) RS55646B1 (show.php)
RU (1) RU2640046C2 (show.php)
SI (1) SI2877177T1 (show.php)
TN (1) TN2015000034A1 (show.php)
UA (1) UA116107C2 (show.php)
WO (1) WO2014016433A1 (show.php)
ZA (1) ZA201501209B (show.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2016057522A1 (en) 2014-10-06 2016-04-14 Flatley Discovery Lab Triazolopyridine compounds and methods for the treatment of cystic fibrosis
PT3699181T (pt) 2014-11-16 2023-04-05 Array Biopharma Inc Forma cristalina de hidrogenossulfato de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN109414442B (zh) 2016-04-04 2024-03-29 洛克索肿瘤学股份有限公司 一种化合物的液体制剂
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3800189T3 (da) 2016-05-18 2023-07-31 Loxo Oncology Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
WO2018049271A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 TrkA阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2019264078A1 (en) * 2018-05-02 2020-12-17 Jw Pharmaceutical Corporation Novel heterocycle derivative
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
WO2024240231A1 (zh) * 2023-05-24 2024-11-28 长春金赛药业有限责任公司 Fgfr2/3选择性抑制剂、药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970084B1 (en) 1997-03-19 2003-06-04 Basf Aktiengesellschaft Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
CA2411961C (en) 2000-06-22 2007-02-06 Pfizer Inc. Novel process for the preparation of pyrazolopyrimidinones
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
JP2009506006A (ja) * 2005-08-25 2009-02-12 エフ.ホフマン−ラ ロシュ アーゲー p38MAPキナーゼ阻害剤およびその使用方法
JP2009543867A (ja) 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗hiv剤としての1−ヒドロキシナフチリジン化合物
MX2009006401A (es) 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
JP5580332B2 (ja) * 2008-12-18 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Also Published As

Publication number Publication date
MX2015001009A (es) 2015-06-04
RU2640046C2 (ru) 2017-12-26
PL2877177T3 (pl) 2017-04-28
US9381195B2 (en) 2016-07-05
ZA201501209B (en) 2016-03-30
EP2877177A1 (en) 2015-06-03
BR112015001502A2 (pt) 2017-07-04
IL236917A (en) 2016-11-30
SI2877177T1 (sl) 2017-02-28
CY1118478T1 (el) 2017-07-12
CA2879595A1 (en) 2014-01-30
CN104684554B (zh) 2017-05-10
ES2612349T3 (es) 2017-05-16
MX363605B (es) 2019-03-26
EP2877177B1 (en) 2016-10-26
MY183398A (en) 2021-02-18
BR112015001502B1 (pt) 2023-03-07
KR102120505B1 (ko) 2020-06-08
UA116107C2 (uk) 2018-02-12
KR20150038295A (ko) 2015-04-08
JP2019031542A (ja) 2019-02-28
EP2689778A1 (en) 2014-01-29
HRP20170104T1 (hr) 2017-03-24
CN104684554A (zh) 2015-06-03
HK1207302A1 (en) 2016-01-29
MA37866B1 (fr) 2016-12-30
NZ705253A (en) 2017-05-26
JP2015522650A (ja) 2015-08-06
RS55646B1 (sr) 2017-06-30
CA2879595C (en) 2020-07-28
PT2877177T (pt) 2017-02-06
AU2013294920B2 (en) 2017-08-24
JP6456823B2 (ja) 2019-01-23
AU2013294920A1 (en) 2015-03-12
JP6732855B2 (ja) 2020-07-29
US20150190394A1 (en) 2015-07-09
DK2877177T3 (en) 2017-02-06
TN2015000034A1 (en) 2016-06-29
MA37866A1 (fr) 2016-05-31
LT2877177T (lt) 2017-01-25
WO2014016433A1 (en) 2014-01-30
RU2015106434A (ru) 2016-09-20

Similar Documents

Publication Publication Date Title
ZA201501209B (en) Derivatives of azaindazole or diazaindazole type for treating pain
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
HUE038382T2 (hu) Kombinációs terápia a szklerózis multiplex kezelésében
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
IL233493A (en) Imidazopyridine derivatives for cancer treatment
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
IL237229A0 (en) Methods of treating cancer using lipoplatin
ZA201409502B (en) Composition for treatment of warts
GB201217890D0 (en) Treatment of cancer
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201208296D0 (en) Treatment of cancer
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment